ES2641291T3 - Composiciones fitoestrogénicas para prevenir o tratar síntomas asociados con menopausia - Google Patents

Composiciones fitoestrogénicas para prevenir o tratar síntomas asociados con menopausia Download PDF

Info

Publication number
ES2641291T3
ES2641291T3 ES08879216.3T ES08879216T ES2641291T3 ES 2641291 T3 ES2641291 T3 ES 2641291T3 ES 08879216 T ES08879216 T ES 08879216T ES 2641291 T3 ES2641291 T3 ES 2641291T3
Authority
ES
Spain
Prior art keywords
menopause
phytoestrogenic
compositions
prevent
symptoms associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08879216.3T
Other languages
English (en)
Inventor
Jae-Soo Kim
Bo-Yeon Kwak
Kwontaek Yi
Jaekyoung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Endotech Co Ltd
Original Assignee
Natural Endotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Endotech Co Ltd filed Critical Natural Endotech Co Ltd
Application granted granted Critical
Publication of ES2641291T3 publication Critical patent/ES2641291T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composición farmacéutica que comprende (a) éster metílico de shanzhisida o una mezcla de ácido cinámico y éster metílico de shanzhisida; y (b) un portador farmacéuticamente aceptable para su uso en la prevención o el tratamiento terapéutico de un trastorno menopáusico, en la que el trastorno menopáusico es enfermedad musculoesquelética, depresión, irritabilidad, enfermedades del sistema genitourinario, enfermedades cardiovasculares o demencia.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
además la mezcla de los mismos muestra un efecto sinérgico en comparación con las sustancias individuales.
Bibliografía
Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med, 14:1062-1071(1994). Greendale GA, Lee NP, Arriola ER. The menopause. Lancet, 353(9152): 571-80(1999).
5 Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. Br Med J, 19: 181-3(1980). Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SS, Snyder TE, et al. Effects of estrogen
replacement on the progression of coronary artery atherosclerosis. N Engl J Med, 343: 522-529(2000). Lien LL, Lien EJ. Hormone therapy and phytoestrogen. J Clin Pharm Ther, 21: 101-11(1996).
10 Brzezinski A, Alercreutz H, Shaoul R. Short term effects of phytoestrogen-rich diet on postmenopausal women. Menopause, 4: 89-94(1997). Elfituri A, Sherif F, Elmahaishi M, Chrystyn H. Two hormone replacement therapy (HRT) regimens for middle-eastern
postmenopausal women. Maturitas., In press, 2005. Edgar D, Staren O, Shuab O. Hormone replacement therapy in postmenopausal women. The American Journal of 15 Surgery, 188: 136-49(2004).
7

Claims (1)

  1. imagen1
ES08879216.3T 2008-12-26 2008-12-26 Composiciones fitoestrogénicas para prevenir o tratar síntomas asociados con menopausia Active ES2641291T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2008/007697 WO2010074361A1 (en) 2008-12-26 2008-12-26 Phytoestrogenic compositions for preventing or treating symptoms associated with menopause

Publications (1)

Publication Number Publication Date
ES2641291T3 true ES2641291T3 (es) 2017-11-08

Family

ID=42287937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08879216.3T Active ES2641291T3 (es) 2008-12-26 2008-12-26 Composiciones fitoestrogénicas para prevenir o tratar síntomas asociados con menopausia

Country Status (12)

Country Link
US (1) US9433595B2 (es)
EP (1) EP2370072B1 (es)
CN (1) CN102264362B (es)
AU (1) AU2008365666B2 (es)
BR (1) BRPI0823391B8 (es)
CA (1) CA2745020C (es)
ES (1) ES2641291T3 (es)
MX (1) MX2011005835A (es)
MY (1) MY184493A (es)
PL (1) PL2370072T3 (es)
RU (1) RU2491926C2 (es)
WO (1) WO2010074361A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101698051B1 (ko) 2016-01-13 2017-01-20 아주대학교산학협력단 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물
RU2736997C1 (ru) * 2019-07-30 2020-11-23 Общество С Ограниченной Ответственностью "Парафарм" Средство для лечения приливов и восстановления менструального цикла в период перименопаузы и способ его применения
CN115671217B (zh) * 2022-11-25 2023-08-01 长春中医药大学 一种治疗绝经前后诸证的中药配方

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US5874084A (en) * 1996-07-19 1999-02-23 Yng-Wong; Quing Non Using complex herbal formulations to treat hot flashes
FR2772612B1 (fr) * 1997-12-19 2003-01-10 Oreal Utilisation de l'acide cinnamique ou de ses derives dans une composition cosmetique raffermissante
US6660283B2 (en) * 1997-12-19 2003-12-09 Societe L'oreal S.A. Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition
CN1303671A (zh) * 1999-11-26 2001-07-18 深圳市御康实业有限公司湖南省分公司 肉桂酸用于制备治疗糖尿病的药物
WO2002032438A1 (fr) * 2000-09-13 2002-04-25 Jiangsu Kanion Pharmaceutical Co. Composition pharmaceutique traitant les maladies gynecologiques associees a la stase sanguine, les maladies cardio-vasculaires et cerebrales, les maladies respiratoires et autres maladies analogues
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
US6664236B2 (en) * 2002-03-19 2003-12-16 Council Of Scientific And Industrial Research Synergistic composition of bioactive fraction isolated from barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof
KR100740566B1 (ko) * 2006-03-13 2007-07-18 경희대학교 산학협력단 페닐프로파노이드 계 화합물을 포함하는 항불안 및 기억력개선 효과를 나타내는 조성물
KR20080093203A (ko) * 2007-04-16 2008-10-21 경희대학교 산학협력단 알기닌, 신남산, 다이드진, 푸에라린, 팔마틴, 베르베린또는 베타-디-글루코피라노사이드로부터 선택된 화합물을유효성분으로 함유하는 골절 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
RU2011130246A (ru) 2013-02-10
RU2491926C2 (ru) 2013-09-10
WO2010074361A1 (en) 2010-07-01
US20110251145A1 (en) 2011-10-13
EP2370072A1 (en) 2011-10-05
PL2370072T3 (pl) 2017-12-29
BRPI0823391B8 (pt) 2021-05-25
BRPI0823391A2 (pt) 2015-06-16
AU2008365666A1 (en) 2011-07-07
EP2370072B1 (en) 2017-06-28
CN102264362A (zh) 2011-11-30
BRPI0823391B1 (pt) 2019-06-18
CA2745020A1 (en) 2010-07-01
CA2745020C (en) 2013-10-15
US9433595B2 (en) 2016-09-06
AU2008365666B2 (en) 2013-05-23
CN102264362B (zh) 2013-10-23
MX2011005835A (es) 2011-07-04
MY184493A (en) 2021-04-01
EP2370072A4 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
BR112019001572A2 (pt) nova formulação administrável por via oral
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
ES2527510T1 (es) Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
JP2010525050A5 (es)
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
HRP20150375T1 (hr) Derivati piridazinona
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
JP2007512371A5 (es)
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
ES2641291T3 (es) Composiciones fitoestrogénicas para prevenir o tratar síntomas asociados con menopausia
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
BRPI0518741A2 (pt) uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
GT200600263A (es) Regimen de dosificacion para prasugrel
JP2020529995A5 (es)
Liang et al. Puerarin prevents tumor necrosis factor-α-induced apoptosis of PC12 cells via activation of the PI3K/Akt signaling pathway